Description: A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Mechanism of Action: TLR7/8 dual agonist (a novel immunotherapy target).
Target Patient Population: All solid tumors.
Study Design: Drug is administered IV weekly in a 21 day cycle